The Role of Adenosine in Chronic Ischemic Cardiomyopathy

腺苷在慢性缺血性心肌病中的作用

基本信息

  • 批准号:
    6802263
  • 负责人:
  • 金额:
    $ 12.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2003
  • 资助国家:
    美国
  • 起止时间:
    2003-09-30 至 2008-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The candidate received superb training in myocardial contrast echocardiography (MCE) and coronary physiology research in Dr. Sanjiv Kaul's experimental laboratory and is committed to the development of an academic career in cardiovascular medicine. The K08 grant would allow her to achieve her immediate career goals, which are to continue to develop expertise in the field of MCE as new ultrasound equipment and microbubbles are developed, to gain an understanding of the pathogenesis of chronic ischemic cardiomyopathy, to learn histopathologic, immunohistochemical, ELISA, EIA, RIA, and SPA techniques, and to become familiar with cardiac MRI as a research tool. Her long-term career goals include development into an independent investigator in the experimental laboratory in the subject of chronic LV dysfunction and MCE, participation in translational research protocols with a focus on chronic ischemia and therapeutics for ischemic congestive heart failure (CHF), and practicing clinical cardiology with an emphasis on coronary artery disease and echocardiography. In sum, she is committed to developing a successful academic career in cardiovascular medicine. CHF is a major health problem in industrialized countries and its prevalence, morbidity, and mortality are rapidly rising. The pathophysiology of ischemic CHF is not well understood. The overall aim of this research proposal is to investigate the role of adenosine in chronic ischemic cardiomyopathy in a canine model of ameroid-induced left ventricular (LV) dysfunction. An A1 allosteric enhancer, a selective A2A agonist and antagonist, and a selective A3 agonist will be given to study their effects on angiogenesis, apoptosis, inflammation, vasodilation, and cardioprotection. At baseline, maximal LV dysfunction, and 1 month, 3 months, and 6 months after administration of the adenosine agonist or antagonist, we will perform MCE to examine myocardial perfusion and angiogenesis, contrast echo imaging of inflammation, MRI to examine myocardial mass, LV volume, and regional and global LV function, microspheres injection to assess myocardial blood flow, and interstitial fluid collection from the myocardium to examine the presence of cytokines and white blood cells. After the 6-month evaluation, histopathology and immunohistochemistry will be performed to correlate functional changes with histologic evidence of inflammatory changes, apoptosis, and angiogenesis. The research environment involves close mentoring by Drs. Kaul and Siragy, use of their lab space, and enthusiastic support from the division chief and consultants, including Dr. Joel Linden who is an authority on the role of adenosine in cardiovascular physiology and pharmacology.
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Dai-Trang Elizabeth Le其他文献

RANOLAZINE EXHIBITS ANTI-ISCHEMIC PROPERTIES BY INCREASING CARDIAC ENDOTHELIAL CELL ADENOSINE LEVELS
  • DOI:
    10.1016/s0735-1097(19)30657-6
  • 发表时间:
    2019-03-12
  • 期刊:
  • 影响因子:
  • 作者:
    Dai-Trang Elizabeth Le;Catherine Davis;Shanthi Nagarajan;Kristin L. Lyon Scott;Zhiping Cao;Helen Liu;Alkayed Nabil;Sanjiv Kaul
  • 通讯作者:
    Sanjiv Kaul
RANOLAZINE RELIEVES ISCHEMIA BY DECREASING MYOCARDIAL WORK WITHOUT ALTERING MYOCARDIAL BLOOD FLOW: INSIGHTS FROM AN EXPERIMENTAL MODEL
  • DOI:
    10.1016/s0735-1097(14)61522-9
  • 发表时间:
    2014-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Dai-Trang Elizabeth Le;Kevin Wei;Yan Zhao;Matthew Nugent;Sanjiv Kaul
  • 通讯作者:
    Sanjiv Kaul
INTRAVENOUS RANOLAZINE RELIEVES ISCHEMIA BY INCREASING MYOCARDIAL ADENOSINE LEVELS
  • DOI:
    10.1016/s0735-1097(15)61571-6
  • 发表时间:
    2015-03-17
  • 期刊:
  • 影响因子:
  • 作者:
    Dai-Trang Elizabeth Le;Kevin Wei;Yan Zhao;Matthew Nugent;Luiz Belardinelli;Sanjiv Kaul
  • 通讯作者:
    Sanjiv Kaul

Dai-Trang Elizabeth Le的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Dai-Trang Elizabeth Le', 18)}}的其他基金

The Role of Adenosine in Chronic Ischemic Cardiomyopathy
腺苷在慢性缺血性心肌病中的作用
  • 批准号:
    7225364
  • 财政年份:
    2003
  • 资助金额:
    $ 12.78万
  • 项目类别:
The Role of Adenosine in Chronic Ischemic Cardiomyopathy
腺苷在慢性缺血性心肌病中的作用
  • 批准号:
    6677645
  • 财政年份:
    2003
  • 资助金额:
    $ 12.78万
  • 项目类别:
The Role of Adenosine in Chronic Ischemic Cardiomyopathy
腺苷在慢性缺血性心肌病中的作用
  • 批准号:
    7259418
  • 财政年份:
    2003
  • 资助金额:
    $ 12.78万
  • 项目类别:
The Role of Adenosine in Chronic Ischemic Cardiomyopathy
腺苷在慢性缺血性心肌病中的作用
  • 批准号:
    7110909
  • 财政年份:
    2003
  • 资助金额:
    $ 12.78万
  • 项目类别:
The Role of Adenosine in Chronic Ischemic Cardiomyopathy
腺苷在慢性缺血性心肌病中的作用
  • 批准号:
    6946495
  • 财政年份:
    2003
  • 资助金额:
    $ 12.78万
  • 项目类别:

相似国自然基金

RGD-68Ga@AuNCs PET监测PRMT5通过VEGFA调节肺腺癌血管新生的功能及机制
  • 批准号:
    82372007
  • 批准年份:
    2023
  • 资助金额:
    48.00 万元
  • 项目类别:
    面上项目
PROCR信号通路介导的血管新生在卵巢组织移植中的作用及机制研究
  • 批准号:
    82371726
  • 批准年份:
    2023
  • 资助金额:
    50.00 万元
  • 项目类别:
    面上项目
ROBO4对视网膜血管生成(angiogenesis)的调控及其分子机制
  • 批准号:
    81200692
  • 批准年份:
    2012
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
基于新生血管显像研究MSC治疗缺血性脑血管病的转化医学关键问题
  • 批准号:
    81171370
  • 批准年份:
    2011
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
探索VASH2转录激活对肝细胞癌血管生成和上皮间质转化的作用及机制
  • 批准号:
    81172267
  • 批准年份:
    2011
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
解析miR-566调控VHL/β-catenin信号通路影响人脑胶质瘤血管新生的分子机制
  • 批准号:
    81101916
  • 批准年份:
    2011
  • 资助金额:
    22.0 万元
  • 项目类别:
    青年科学基金项目
脂肪组织来源干细胞促进颗粒脂肪游离移植后再血管化机制的实验研究
  • 批准号:
    81171834
  • 批准年份:
    2011
  • 资助金额:
    58.0 万元
  • 项目类别:
    面上项目
99mTc-3PRGD2 SPECT显像用于评价肺癌抗新生血管药物疗效的动物研究及肺癌诊断临床研究
  • 批准号:
    81171369
  • 批准年份:
    2011
  • 资助金额:
    56.0 万元
  • 项目类别:
    面上项目
核素靶向示踪肿瘤新生血管作用位点研究
  • 批准号:
    81071183
  • 批准年份:
    2010
  • 资助金额:
    32.0 万元
  • 项目类别:
    面上项目
TEM8-Fc抗肿瘤机理的研究
  • 批准号:
    30973670
  • 批准年份:
    2009
  • 资助金额:
    32.0 万元
  • 项目类别:
    面上项目

相似海外基金

The Adenosinergic Pathway in Tumor-derived Exosomes
肿瘤源性外泌体中的腺苷能途径
  • 批准号:
    10589774
  • 财政年份:
    2021
  • 资助金额:
    $ 12.78万
  • 项目类别:
The Adenosinergic Pathway in Tumor-derived Exosomes
肿瘤源性外泌体中的腺苷能途径
  • 批准号:
    10374743
  • 财政年份:
    2021
  • 资助金额:
    $ 12.78万
  • 项目类别:
Role of Adenosine in TGF-beta Effects in Cancers
腺苷在癌症中 TGF-β 效应中的作用
  • 批准号:
    9310426
  • 财政年份:
    2016
  • 资助金额:
    $ 12.78万
  • 项目类别:
ENTPD1: A Candidate Susceptibility Gene for Renovascular Disease
ENTPD1:肾血管疾病的候选易感基因
  • 批准号:
    7993859
  • 财政年份:
    2009
  • 资助金额:
    $ 12.78万
  • 项目类别:
Neonatal Morphine: Long-term Cerebrovascular Effects
新生儿吗啡:长期脑血管影响
  • 批准号:
    7386211
  • 财政年份:
    2008
  • 资助金额:
    $ 12.78万
  • 项目类别:
Neonatal Morphine: Long-term Cerebrovascular Effects
新生儿吗啡:长期脑血管影响
  • 批准号:
    7623223
  • 财政年份:
    2008
  • 资助金额:
    $ 12.78万
  • 项目类别:
ENTPD1: A Candidate Susceptibility Gene for Renovascular Disease
ENTPD1:肾血管疾病的候选易感基因
  • 批准号:
    7433740
  • 财政年份:
    2007
  • 资助金额:
    $ 12.78万
  • 项目类别:
ENTPD1: A Candidate Susceptibility Gene for Renovascular Disease
ENTPD1:肾血管疾病的候选易感基因
  • 批准号:
    8107694
  • 财政年份:
    2007
  • 资助金额:
    $ 12.78万
  • 项目类别:
ENTPD1: A Candidate Susceptibility Gene for Renovascular Disease
ENTPD1:肾血管疾病的候选易感基因
  • 批准号:
    7910634
  • 财政年份:
    2007
  • 资助金额:
    $ 12.78万
  • 项目类别:
ENTPD1: A Candidate Susceptibility Gene for Renovascular Disease
ENTPD1:肾血管疾病的候选易感基因
  • 批准号:
    7314486
  • 财政年份:
    2007
  • 资助金额:
    $ 12.78万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了